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Summary
Objective: Identification, quantification and isolation of subpopulations with characteristics of mesenchymal progenitor cells (MPC) from the
synovial membrane (SM) from patients with osteoarthritis (OA).
Method: Cells from the SM of patients with end stage OA who underwent total knee joint replacement were enzymatically isolated. One
aliquot was directly analyzed by fluorescence automated cell sorting (FACS) using various combinations of surface markers of bone marrow
MPC (CD9, CD44, CD54, CD90, and CD166). Remaining cells were cultivated on plastic, expanded over several passages, analyzed by
FACS again and tested for their osteo- and chondrogenic potential. The differentiation was analyzed by immuno-/histochemistry and by
RT-PCR for the expression of lineage related marker genes.
Results: Using FACS analysis we could show that the relative proportion of subpopulations expressing triplicate combinations of CD9, CD44,
CD54, CD90 and CD166 in the SM from OA patients varies between 3 and 10%. Upon cultivation their relative amount markedly increased
to values between 24 and 48%. Within the heterogeneous cell populations it was possible to induce osteogenic and chondrogenic
differentiation. Initial sorting for CD9/CD90/CD166 triplicate positive cells proved that this subpopulation contains cells with multipotency for
mesenchymal differentiation and thus characteristics of MPC.
Conclusion: Our results show that SM from OA patients contains cells that express typical combinations of MPC surface markers and have
the potency of osteogenic and chondrogenic differentiation. Their relative enrichment during in vitro cultivation and the possibility of cell
sorting to get more homogenous populations offer interesting perspectives for possible future therapeutic applications.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Mesenchymal progenitor cells (MPC) have first been
identified in bone marrow by their ability to differentiate in
various phenotypes of connective tissue including carti-
lage, bone and adipose tissue1,2. During the last years this
cell population received rapidly growing interest by its
possible involvement in repair processes and its potential
as a cellular source of tissue replacement approaches3–5.
This led to a more precise characterization by analysis
of cell surface markers and differentiation related gene
expression6,7. In parallel it was recognized that MPC not
only reside in bone marrow, but also in various other
connective tissues like periost, adipose or muscle tissue7,8.
Driven by the clinico-pathological observation of synovial
chondromatosis it was suggested that MPC are also
present in synovial tissue. This could be proved by the
demonstration of the potential for chondrogenic differ-
entiation in tissue and cells derived from rabbit synovial
membrane (SM)9,10. In cell populations derived from hu-
man SM a differentiation into the chondrogenic, osteogenic,
and adipogenic phenotypes was also described11. The
detection of MPC in human SM is an important issue since
it demonstrates the presence of cells principally capable of
cartilage tissue repair within the joint. Moreover, this cell
population might serve as a source of novel cell-based
therapeutic approaches for cartilage injury or degenerative
joint disease. Future studies in that direction, however,
need a more detailed characterization of these cells and
methods to specifically identify, quantify and isolate MPC
from SM. Therefore, we analyzed the expression of cell
surface markers described for MPC from bone marrow in
cells derived from SM of osteoarthritic joints7,12. We used
these markers for quantification of subpopulations by
flow cytometric analysis in the original cell population and
after attachment and in vitro cultivation. Finally, we sorted
these cells according to the expression of triplicate MPC
surface markers and we could demonstrate that this sub-
population is capable of osteogenic and chondrogenic
differentiation.
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Materials and methods
PATIENT CHARACTERISTICS
Human SM was derived from routine surgical procedures
(during total knee replacement) with informed consent from
five female and five male patients with end stage osteoar-
thritis (OA) in accordance with the terms of the ethics
committee of the University of Ulm. The age of the donors
ranged from 55 to 82 years (mean 70 years). The diagnosis
was based on clinical and radiological criteria. None of the
donors had received corticosteroids or cytostatic drugs
during previous months. Patients with systemic inflam-
matory diseases like rheumatoid arthritis or spondylarthro-
pathies were excluded.
CELL ISOLATION, EXPANSION AND CRYOPRESERVATION
For cell culture SM samples were rinsed twice with
PBS (Invitrogen, Karlsruhe, Germany) supplemented with
antibiotic solution (100 units/ml penicillin, 100 µg/ml strep-
tomycin; Biochrom, Berlin, Germany) to eliminate contami-
nating blood cells, minced finely and digested with 0.4%
collagenase (Roche, Mannheim, Germany) for 1 h at 37°C.
After filtration through a 40 µm pore membrane, the cells
were washed twice in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Karlsruhe, Germany) containing 10%
fetal calf serum (FCS; Biochrom, Berlin, Germany) and
antibiotic solution (100 units/ml penicillin, 100 µg/ml
streptomycin), counted and plated at low density containing
5×104 isolated cells/cm2.
DMEM supplemented with 10% FCS was used as a
medium during the proliferation phase. The cultures were
incubated at 37°C in a humidified 5% CO2 atmosphere and
media were changed three times a week. Cultures were
split 1:2 by trypsin treatment (0.05% trypsin, 0.02% EDTA;
Biochrom, Berlin, Germany) at 75% confluence.
FLOW CYTOMETRY ANALYSIS OF CELLS
Either isolated cells from SM were directly used for flow
cytometric analysis, or after adherence and cultivation as
described above. Cells were washed twice with PBS con-
taining 1% FCS and 0.02% sodium azide (Sigma,
Taufkirchen, Germany). The cells were incubated with 1 µg
per 106 cells of each mouse anti-human monoclonal anti-
body that had been directly conjugated to a fluorochome or
biotinylated in the dark for 20 min on ice. The following
antibodies were used for first staining: CD9 and CD45
fluorescein isothiocyanate (FITC) labeled, CD44, CD90,
CD133/1, and CD133/2 biotin labeled, CD54 and CD166
phycoerythrin (PE) labeled. After a washing step, second
staining for biotin-conjugated Mabs was done with
Streptavidin PerCP conjugate in working titer 1:100. After
30 min in the dark on ice, cells were washed again twice
with PBS buffer before flow cytometric analysis. MPC were
characterized by three-color immunofluorescence and
2×104 cells per sample were analyzed on a Becton
Dickinson FACScalibur using CELLQuest software. Dead
cells were excluded by propidium iodide (PI; Sigma,
Taufkirchen, Germany) staining. Cells were gated on for-
ward and side scatter to exclude debris and cell aggre-
gates. To calculate the percentage of cells positive staining
for antigen specific FITC-conjugated, PE-conjugated, APC-
conjugated or Biotin-conjugated Mabs, markers were set in
the channel display maximal 2% positive cells by staining
with isotype control antibody.
CD133/1 (AC133)-Biotin, CD133/2(AC141)-Biotin was
obtained from Miltenyi Biotec (Bergisch-Gladbach,
Germany). All other antibodies and the isotype controls
FITC mouse IgG1, R-PE mouse IgG1, biotin mouse
IgG1, biotin mouse IgG2b were provided by Becton
Dickinson (Heidelberg, Germany).
FLUORESCENCE-ACTIVATED CELL SORTING
For cell sorting, native isolated cells from SM were
stained with saturating concentrations of CD9-FITC, CD90-
allophycocyanine (APC) and CD166-PE. Single cells
were sorted into the flow cytometry tubes (Becton
Dickinson, Heidelberg, Germany) using a Becton Dickinson
FACStarplus cell sorter. SM cells were gated based on
forward and side scatter and the frequencies of CD90+ and
CD166+ cells were determined following a second gate on
CD9+ cells.
IN VITRO CHONDROGENESIS ASSAY
Micromass cultures were performed as described else-
where13,14. Briefly, expanded SM-derived cells and sorted
SM cells were released by trypsin treatment, counted and
resuspended in 15 ml polypropylene conical tubes at a
density of 2×105–1×106 and short spun down at 500g.
Medium was changed to 500 µl DMEM with 10% FCS, 1%
antibiotic mix (penicillin/streptomycin), 37.5 µg/ml (100 µM)
L-ascorbic acid-2 phosphate and 10−7 M dexamethasone.
Micromass cultures were incubated with 10 ng/ml recom-
binant human transforming growth factor 3 (rhTGF 3;
Tebu, Offenbach, Germany), which was added to the
medium for the first 7 days. All cultures were maintained at
37°C in 5% CO2 and the media were changed every third
day. After 3 weeks, the samples were used for histological
and immunohistological studies as well as RT-PCR gene
expression analysis.
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
The samples were fixed in 4% PFA and embedded
in paraffin. For histological evaluation, sections were
deparaffinized and either stained with hematoxylin (HE) or
Alcian blue at pH 2.5 with an additional Kernechtrot
counterstaining, according to standard protocols.
For immunohistochemical analysis of collagen type I, II
and COMP in chondrogenic differentiated micromass cul-
tures, 3 µm sections were deparaffinized and treated with
1 mg/ml pepsin (Sigma, Taufkirchen, Germany) in 0.5 M
acetic acid for collagen type I, 500 µg/ml proteinase K in
TBS (Sigma, Taufkirchen, Germany) for collagen type II, or
1 mg/ml hyaluronidase (Sigma, Taufkirchen, Germany)
and proteinase K (500 µg/ml in TBS) for COMP at room
temperature for different times to facilitate antibody
access. Endogenous peroxidase was blocked by 3%
H2O2. Incubating the slides for 30 min in blocking reagent
blocked nonspecific binding. Sections were then incubated
overnight at 4°C with primary antibodies. Rabbit anti-
human polyclonal antibodies against collagen type I (DPC
Biermann, Bad Nauheim, Germany), collagen type II (DPC
Biermann), and COMP (kindly provided by Dr F. Zaucke
and Prof M. Paulsson, Institute for Biochemistry II,
University of Ko¨ln, Germany) were used. The antibody
directed against collagen type I was diluted 1:1000, the
antibody against collagen type II was diluted 1:400, and the
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antibody against COMP was used at a 1:300 dilution in 1%
BSA in PBS. Biotinylated antimouse/antirabbit secondary
antibodies were used for 30 min incubation followed by
30 min streptavidin treatment. Finally, sections were
stained using the AEC kit (DAKO, Hamburg, Germany)
according to the manufacturer’s instructions. Nuclei were
counterstained with HE.
IN VITRO OSTEOGENESIS ASSAY
After trypsin treatment 2×104 cells were washed in
DMEM with 10% FCS, cultured in six well plates (Becton
Dickinson). Medium for osteogenic differentiation con-
taining DMEM with 0.1 µM dexamethasone, 10 mM
-glycerophosphate, 50 µg/ml L-ascorbic acid 2 phosphate
was changed every third day. Osteogenic differentiation
was proofed by ‘von Kossa’ staining and RT-PCR gene
expression analysis.
RT-PCR AND ANALYSIS OF GENE EXPRESSION
Total RNA was isolated from fresh SM, which was cut into
small pieces, or cultivated cells and lysed in 600 µl lysis
buffer with 6 µl mercaptoethanol, by using the RNeasy®
system and reverse transcription was done with
Omniscript™ RT Kit (all QIAGEN®, Hilden, Germany)
following the manufacturer’s instructions.
PCR reactions were performed with a Robocycler®
(Stratagene, Amsterdam, The Netherlands) using
HotStarTaq™ Master Mix Kit (QIAGEN®, Hilden,
Germany). PCR was performed under linear conditions
using the cycle profile: initial incubation 15 min at 95°C,
followed by 30 cycles annealing 45 s at 60°C, extension
45 s at 72°C, denaturation 60 s at 94°C, and terminating
with 15 min at 72°C. PCR products were separated on a
1.5% agarose gel and stained with ethidium bromide,
visualized and digitalized with an ImageMaster VDS sys-
tem (Amersham Pharmacia Biotech, Freiburg, Germany).
The primer sequences are shown in Table I.
Results
FLOW CYTOMETRIC ANALYSIS OF CELLULAR SUBPOPULATIONS
FROM SYNOVIAL MEMBRANE
The cell populations from SM were characterized by
staining for surface marker proteins, described previously
for MPC from bone marrow7. From the set of accepted
markers we choose seven different cell surface markers
and stained freshly isolated cells from SM directly with
seven different triple combinations (Table II).
As shown in Fig. 1, within the CD9+/CD90+/CD166+
analysis only about 1–3% of the cells were stained triple
positive.
The isotype control antibody that shows no specific
staining and the distributions of SM cells in forward/side
scatter are presented in Fig. 2.
The majority of the cells stained negative for CD9, CD90
and CD166. The CD9− and CD166− cells could be sub-
divided into two equivalent populations comprising about
30% of total cells that were either positive or negative for
CD90. Phenotypic analysis showed no significant expres-
sion of CD9+, CD90+, and CD166− cells. The CD9+ and
CD166+ cells could be subdivided into 3% CD90 positive
and 1.5% negative out of total cells.
The combinations of CD45+/CD90+/CD166+ and CD9+/
CD133+/CD166+ showed no significant staining. The
majority of the cells negative for the CD45− were variable
regarding the expression of CD90 [Fig. 2(D)]. MPC cultures
from bone marrow of different donors served as controls. In
these samples 95–98% of all gated cells were triple positive
for various combinations of the markers CD9/CD54/CD90/
CD166 (data not shown).
ANALYSIS OF SYNOVIAL CELLS AFTER ADHERENCE AND
CULTIVATION
The change in cellular morphology and the acquisition
of a fibroblastic shape was progressively apparent as the
cells were cultured on plastic. In the primary culture
Table I
Primers used in this study
Target 5′–3′ Source
AP ACC TCG TTG ACA CCT GGA AG
CCA CCA TCT CGG AGA GTG AC
Based on accession No.: X95994
BSP TGC ATT GGC TCC AGT GAC ACT
TGC TCA GCA TTT TGG GAA T
Based on accession No.: XM_032432
Col1 TAA CTT CTG GAC TAT TTG CGG ACT TTT GG
CAA CCT CAG CCC ATT GGC GCT G
Based on accession No.: NM_000088
GAPDH CGG AGT CAA CGG ATT TGG TCG TAT
AGC CTT CTC CAT GGT TGG TGA AGA C
Based on accession No.: NM_002046
OCN CTG GCC CTG ACT GCA TTC TGC
AAC GGT GGT GCC ATA GAT GCG
Based on accession No.: X53699
For primer design Primer3 was used (Steve Rozen, Helen J. Skaletsky, 1998; available at http://www-genome.wi.mit.edu/genome_
software/other/primer3.html with published DNA sequences from GenBank; NCBI).
Table II
Cell surface markers used for FACS analysis
CD locus Detection of MPC Common name
CD9 Positive Tetraspan
CD44 Positive HCAM
CD54 Positive ICAM-1
CD90 Positive Thy-1
CD166 Positive ALCAM
CD133 Negative AC133
CD45 Negative Leukocyte common antigen
MOPC-21 – IgG1 isotype control
27–35 – IgG2b isotype control
The classification MPC surface marker was done in conformity
with previous publications7,12.
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non-adherent or few loosely adherent small round cells,
positive for the hematopoietic antigen CD45, were also
present, but disappeared after the second to third pas-
sage. Following isolation, during the first 6 h most of the
later rapid growing cells adhered. After 36 h only a few
SM cells became adherent and expanded later very
slowly (data not shown). After an initial lag time of 2–3
days, cells entered a proliferative phase, reaching 75%
confluence within 48–72 h. An average of one doubling
per 3 days was observed upon subsequent passages.
In order to determine the percentage of culture expanded
progenitor cells that express antigens recognized by
Fig. 1. FACS analysis of freshly isolated SM cells and isotype control. Distribution of fresh isolated SM cells in forward/side scatter (A).
Markers were set in the channel display with a maximum of 2% positive cells by staining with isotype control antibody FITC-conjugated
mouse IgG1 (B). The triple staining experiments were shown for CD9-FITC/CD90-APC/CD166-PE (C–E). According to histogram of FL1
CD9-FITC (C) cells were divided into CD9 negative and positive stained. CD9 negative, double-stained CD90-APC/CD166-PE cells are
shown in (D) and CD9 positive, double-stained CD90-APC/CD166-PE fresh isolated SM cells are shown in (E).
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CD9/CD44/CD54/CD90/CD166 monoclonal antibodies, the
number of immunoreactive cells was quantified by flow
cytometry. Data from adherent, culture expanded cells
were collected from five donors, and the number of triple
positive events was expressed as a percentage of the total
cell number. In these experiments, the mean frequency of
every triple positive staining of cultured SM cells markedly
increased (Fig. 3).
Figure 4 shows the FACS analysis from the patient with
the highest amount of triple positive cells (92% of total
cells) after cultivation.
The total frequency of the CD9+/CD90+/CD166+ popu-
lation rises up to 4.2-fold compared to freshly isolated SM.
After cultivation in monolayer, more than 5.5-fold CD9+/
CD44+/CD54+ cells compared to native, uncultured triple
positive cells were found. Within the in vitro expanded cells,
CD45+ was still not detectable, whereas total frequency of
CD45−/CD90+/CD166+ population was around 37%. These
results indicate that adherence on plastic and cultivation
enriches a subpopulation of SM cells that expresses cell
surface markers of MPC.
DIFFERENTIATION OF PROGENITOR MARKER SORTED POSITIVE
CELLS
The results suggested that there is a subpopulation in the
SM, which expresses progenitor-associated markers and
enables an osteogenic and chondrogenic differentiation.
This differentiation potential would likely be found among
cells triplicate positive for MPC cell surface markers. Based
Fig. 2. FACS analysis of freshly isolated SM cells of CD45-FITC/CD90-APC and CD166-PE. FSC/SSC used the same gate for all
experiments (A). Histogram of cells stained with isotype control antibody FITC-conjugated mouse IgG1 (B) and CD45-FITC (C). CD45
negative, double-stained CD90-APC/CD166-PE cells are shown in (D) and CD45 positive, double-stained CD90-APC/CD166-PE fresh
isolated SM cells are shown in (E).
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on the phenotypic analysis by FACS, we therefore iso-
lated as an example CD9+/CD90+/CD166+ SM cells and
analyzed the differentiation potential. The gates used for
cell sorting are shown in Fig. 5.
In these experiments the mean frequency of native
CD9+/CD90+/CD166+ population was 5%. Figure 5(A)
shows the forward and side scatter characteristics of sorted
SM cells. Figure 5(B–D) shows the CD9-FITC/CD90-APC
or CD166-PE double positive cells and the fluorescence
gate used for sorting. To proof the quality of sorting,
reanalysis of triple positive sorted cells was performed and
revealed 94% triple positive for events [Fig. 5(E and F)].
Serial observations of each culture well that contained triple
positive cells were performed after 3, 7, 14, 21 and 28
days. The earliest point at which the growth of triple positive
sorted could be detected was after 3 days. Between 7 and
14 days of culture, adherent, fibroblast-like cells scattered
in a random pattern across the surface of the culture well.
For 21 days of culture continuous growth of the adherent,
fibroblastic cells was observed.
OSTEOGENESIS AND CHONDROGENESIS OF CULTURE EXPANDED
SM CELLS
The differentiation potential of the cultured SM and
sorted cells were proved by RT-PCR, histo- and immuno-
histochemistry. Micromass cultures of SM-derived cells
resulted in the formation of dense nodules consistent
with chondrogenic differentiation. These nodules were
associated with an Alcian blue-positive ECM, indicative of
the presence of sulfated proteoglycans within the matrix
[Fig. 6(A and B)].
Cartilaginous nodules were also observed upon micro-
mass cultures of bone marrow derived MPC. In addition
to the presence of sulfated proteoglycans within the ECM,
TGF3 supplemented SM-derived cells expressed colla-
gen type II and COMP in micromass culture [Fig. 6(C–F)].
In micromass cultures from expanded cells and FACS
sorted cells the collagen type II staining differs slightly. In
the cells not sorted the staining appears more diffuse all
over the micromass bead, whereas in the micromass of
sorted cell cultures the collagen type II was predominantly
in the inner areas [Fig. 6(E and F)]. Overall, these
results indicate that a subpopulation of SM-derived cells
has the capacity to differentiate toward the chondrogenic
lineage.
Differentiation of SM-derived cells into osteoblasts was
induced in vitro by treating the cells with ascorbic acid,
-glycerophosphate, and dexamethasone2,15,16. SM-
derived cells and bone marrow MPC formed an extensive
network of dense, multilayered nodules that stained
positive for AP (data not shown) and von Kossa
[Fig. 6(G and H)]. Consistent with osteogenesis, several
black regions, indicative of a calcified ECM, were observed
in SM cells and bone marrow MPC. In non-supplemented
cell cultures no staining appeared.
After 14 days of differentiation, gene expression of osteo-
blast markers was investigated. For SM cells and bone
marrow MPC we could detect a strong signal for gene
expression of all tested osteogenic markers, AP, BSP and
OC (Fig. 7).
Therefore, the expression of AP by SM cells, the
production of a calcified ECM and the osteogenic gene
expression profile strongly indicate that these cells can be
differentiated toward the osteoblastic lineage.
Discussion
Cells from SM were enzymatically isolated, directly
analyzed by FACS or introduced into monolayer cell
culture. The relative amount of cells being triplicate positive
for MPC surface markers was 3–10% after isolation and
increased by a factor of about three to seven after
Fig. 3. Flow cytometric analysis of combinations of progenitor markers on freshly isolated SM cells and culture expanded SM cells. Data
presented as means±SD. All native marked SM cells are from freshly isolated SM from eight donors and the amount of total triple positive
cells of five donors after cultivation as described in Materials and methods.
Osteoarthritis and Cartilage Vol. 11, No. 11 795
adherence on plastic and cultivation. Using differentiation
protocols for MPC from bone marrow we could show
that among culture expanded SM cells as well as the
initially sorted CD9/CD90/CD166 positive subpopulation
there is the potential for osteogenic and chondrogenic
differentiation.
Besides their multipotency for mesenchymal differ-
entiation Pittenger et al. and Azizi et al. reported about the
phenotypic characterization of bone marrow MPC by the
expression of several surface markers2,17. MPC express a
large number of adhesion molecules like ALCAM (CD166),
the hyaluronate receptor (CD44) and ICAM-1 (CD54),
growth factor and cytokine receptors, integrins and
additional markers like Tetraspan (CD9) or Thy-1 (CD90)7.
In contrast, CD34 and the leukocyte common antigen
CD45 representing the hematopoietic lineage are not
expressed by ex vivo culture expanded MSC4. The early
hematopoietic lineage as well as the endothelial progenitor
cells are also characterized by the expression of CD13318.
Despite the expanding knowledge on the biology of
MPC, until now it is not possible to characterize these cells
by one single marker. Instead, the parallel expression or
exclusion of several cell surface markers associated with
the multipotency of mesenchymal differentiation may be
more appropriate. Based on these criteria the progenitor
phenotype of a low percentage of SM cells was suggested
Fig. 4. FACS analysis of culture expanded SM cells from the patient with the highest relative amount of triple positive cells after cultivation.
FSC/SSC of analyzed cultured cells (A). Histogram of FITC-mIgG1 (B) and CD9-FITC (C) stained cells. Dot plots are showing the expression
of triple stained cells: FITC-mIgG1 positive gated PE-mIgG1/biotin-mIgG1 (D), CD9-FITC gated positive, double-stained CD90-biotin/
CD166-PE (E).
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in our experiments by the positive reactivity to a combi-
nation of established markers. For FACS analysis and cell
sorting we used various triple combinations of CD9/CD44/
CD54/CD90/CD166. Although the amount of total triple
positive cells varied to some extent between the chosen
combinations our results indicated the presence of a
certain cell population expressing all five markers of bone
marrow MPC in parallel.
After adherence on plastic and monolayer cultivation of
isolated SM cells the specific subtype of cells staining triple
positive for MPC markers enriched markedly. In contrast,
cells of the hematopoietic lineage, staining positive for
CD45, did not significantly increase. As well, cells negative
for CD45 and double positive for CD90 and CD166
increased 30–40 fold. Thus this triple positive subtype of
SM cells seems to have an advantage of selection or the
expression of these cell surface markers is induced in
certain subpopulations during in vitro cultivation. This
clearly deserves further investigation.
In agreement with De Bari et al. we found a relative
homogenous cell morphology during cultivation of enzy-
matically isolated SM cells11. Our results however clearly
demonstrate that on the level of cell surface marker expres-
sion there is a considerable heterogeneity. Initially only a
Fig. 5. Reanalysis of triple positive sorted cells. Forward and side scatter characteristics of sorted SM cells (A). CD9-FITC/CD166-PE,
CD9-FITC/CD90-APC or CD90-APC/CD166-PE double positive cells and the fluorescence gate used for previous cell sorting (B–D). Triple
staining of CD9 positive, CD90/CD166 (E) and CD9 negative, CD90/CD166 (F).
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Fig. 6. Differentiation of culture expanded SM cells and CD9/CD90/CD166 sorted SM cells. Chondrogenic differentiation of culture expanded
(A,C,E) and sorted SM cells (B,D,F) was proved by Alcian blue staining (A,B), COMP (C,D) and collagen type II (E,F) staining of micromass
cultures. In addition, von Kossa staining of native SM cells after osteogenic differentiation in monolayer is shown (G, H). Magnification:
A–F 100×; G 200×; H 400×.
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few percent of freshly isolated cells from SM expressed
MPC typical combinations of surface markers and even
after four to six passages with the exception of one patient
(shown in Fig. 4) the majority of cells did not belong to the
triple positive fractions. In agreement with our results
Zimmermann et al. recently reported the enrichment of
CD90 positive cells during cultivation of synovial fibro-
blasts19. In this study synovial tissue was not derived from
osteoarthritic patients but from patients with rheumatoid
arthritis. This report did not concentrate on the identification
of MPC and therefore other MPC markers were not
described.
From the clinical observation of synovial chondromatosis
and previous studies using tissue and cell culture tech-
niques is well known that the SM contains chondrogenic
progenitor cells10,11. Subsequent to De Bari et al., this is
the second report that among SM cells from patients with
OA there are those also capable for osteogenic differ-
entiation11. In addition, we identified the potential for osteo-
chondral differentiation within a subpopulation expressing
CD9, CD90 and CD166. So far we do not know exactly,
whether in this subpopulation the relative amount of
multipotent MPC is really enriched. Our studies concerning
chondrogenic and osteogenic differentiation did not reveal
major differences between sorted and unsorted SM cells. It
has to be taken into account, however, that clonal analysis
of bone marrow MPC revealed a heterogeneous differ-
entiation potential20. Further studies concerning the
question of differentiation potency of unsorted, positively
sorted and negatively sorted cells are necessary to address
that important question. This knowledge may set the basis
for further work on special subpopulations of mesenchymal
progenitors, including the opportunity for stimulating their
proliferation, chemotaxis and differentiation in order to
facilitate a repair process within the joint. Hunziker et al. for
example could demonstrate that a recruitment of progenitor
cells from the SM for a repair process is triggered by
TGF110.
Our results indicate that cells with characteristics of MPC
can be isolated from SM of human osteoarthritic joints.
They might serve as an alternative cellular source for
cell-based tissue engineering of cartilage. Important
requirements for such approaches are suitable tools for the
isolation, enrichment or cell sorting and characterization of
the target cells. In that context approaches using FACS are
very promising as demonstrated by the work presented
here. Moreover, possible future therapeutic studies need
a sufficient characterization of MPC used to allow a
comparison between different studies.
We identified an MPC population capable of bipotential
osteochondral differentiation. The combinations of MPC
specific cell surface markers used could serve as a tool to
isolate and identify MPC from osteoarthritic synovial tissue.
Further characterization of the cell-biologic behavior of this
subpopulation is necessary to evaluate its potential for
novel approaches of cartilage repair or regeneration. More-
over, the pathogenetic role of MPC in the osteoarthritic
process is still unclear. Recently it has been described that
MPC from bone marrow have reduced chondrogenic and
adipogenic potential in advanced OA21. Our results indi-
cate, that MPC from SM from end stage OA patients have
at least retained a certain capacity for chondrogenic differ-
entiation that may open new therapeutic perspectives in the
future.
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